Other Events. At the Shareholder Meeting on August 26, 2026, Cyclerion’s shareholders approved the Reverse Stock Split Proposal. Following this approval, the Cyclerion Board approved the reverse stock split of Cyclerion’s issued and outstanding common stock at a final ratio, agreed to by Korsana, of 1-for-7 shares of Cyclerion common stock (the “Reverse Stock Split”). Prior to the closing of the Merger, Cyclerion will file articles of amendment to the Cyclerion Articles with the Secretary of…

Other Events. On August 25, 2026, the board of directors of Cyclerion Therapeutics, Inc. (the “Company”) fixed the close of business on September 4, 2026 as the record date for the Company’s previously announced distribution (the “CVR Distribution”) of contingent value rights (“CVRs”) to holders of record of the Company’s common stock and the Company’s Series A Preferred Stock, in connection with the Company’s planned merger (the “Merger”) with Korsana Biosciences, Inc. (“Korsana”). Forward-L…

Regulation FD Disclosure. On April 1, 2026, Cyclerion and Korsana issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Furnished as Exhibit 99.2 hereto and incorporated herein by reference is the investor presentation that wil…

Changes in Control of Registrant. To the extent required by this Item, the information included in

Entry into a Material Definitive Agreement. Merger Agreement On April 1, 2026, Cyclerion Therapeutics, Inc., a Massachusetts corporation (“ Cyclerion ”), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Cyclerion (“ First Merger Sub ”), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Cyclerion (“ Second Merger Sub ” and, together with First Merger Sub, “ Merger Sub ”), and Korsana Biosciences, Inc., a Delaware…

The filing appears to be a placeholder or incomplete, not detailing any specific management change.

Entry into a Material Definitive Agreement. On January 3, 2026, Cyclerion Therapeutics, Inc. (the “Company”) and the Medsteer, SAS (“Medsteer”) entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii) an exclusive opti…

Regulation FD Disclosure On January 5, 2026, the Company issued a press release announcing its entry into the Collaboration Agreement and providing an update on the development of CYC-126, its lead product candidate. In addition, the Company has prepared an investor presentation with respect to the License Agreement and update on CYC-126. A copy of the press release and investor presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively, and in…

Other Events On December 1, 2025, Akebia Therapeutics, Inc. (“Akebia”) publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (“FSGS”) using Praliciguat, an oral soluble guanylate cyclase licensed to Akebia by Cyclerion Therapeutics, Inc. (Cyclerion”). Pursuant to the terms of Amendment #1 to the License Agreement by and between Akebia and Cyclerion, upon initiation (defined as first patient dosed) of a Phase 2 clinica…

Entry into a Material Definitive Agreement. On September 19, 2025, Cyclerion Therapeutics, Inc. (the “Company”) and the Massachusetts Institute of Technology (“MIT”) entered into a Patent License Agreement (the “License Agreement”) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the terms of the License Agreement, the…

Entry into a Material Definitive Agreement. On May 7, 2025, Cyclerion Therapeutics, Inc. (the “Company”) and Guggenheim Securities, LLC (“Guggenheim Securities”) entered into a Sales Agreement (the “Sales Agreement”), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the “Shares”), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company’s agent, subject to the applicatio…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Stock Purchase Agreement On March 21, 2025, Cyclerion Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the investors named therein, including Peter Hecht and Michael Higgins, who serve as members of the Company’s Board of Directors (each, an “ Investor ” and collectively, the “ Investors ”) for the private placement of 499,998 shares (the “ Shares ”) of the Company’s common stock, no par…

ENTRY INTO A MATERIAL AGREEMENT On December 13, 2024, Cyclerion Therapeutics, Inc. (the “Company” or “Cyclerion””) and Akebia Therapeutics, Inc. (“Akebia”) entered into Amendment #1 to License Agreement (the “Amendment”) to the original License Agreement between the parties dated June 3, 2021 (the “2021 License Agreement”). Under the terms of the Amendment, Akebia has agreed to pay to the Company (i) $1,250,000 before December 31, 2024, and (ii) $500,000 on or before September 30, 2025. In ad…

President — Regina Graul Ph.D.: Regina Graul was promoted to President, replacing Peter Hecht who resigned but will continue as a consultant and board member.

Director — Michael Higgins, Dina Katabi, Ph.D.: The Board of Directors increased its size and elected two new independent directors.

Director — Ole Isacson, M.D., Ph.D.: Dr. Ole Isacson resigned as a director of the company.

Chief Financial Officer — Anjeza Gjino: Ms. Gjino resigned from her position as Chief Financial Officer with a severance package.

Other Events. As previously disclosed, on May 11, 2023, Cyclerion Therapeutics, Inc., a Massachusetts corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with JW Celtics Investment Corp., a Delaware corporation (“ Buyer Parent ”) and JW Cycle Inc., a Delaware corporation (“ Buyer ” and, together with Buyer Parent, “ Buyers ”), pursuant to which the Company agreed, subject to certain conditions, including the authorization and approval of t…

Chief Operating Officer — Cheryl Gault: Ms. Gault resigned to pursue other opportunities.

Unregistered Sales of Equity Securities. As previously announced, on March 31, 2023, Cyclerion Therapeutics, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with Peter M. Hecht, Ph.D., the Company’s Chief Executive Officer and a member of the Board, for him to make an equity investment in the Company of $5,000,000 in cash for shares of common stock (“Common Stock”) and nonvoting Series A convertible preferred stock (“Series A Preferred Stock”) of the Co…

Material Modification to Rights of Security Holders. To the extent required by

Other Events. Voting and Support Agreements Simultaneously with the execution of the Asset Purchase Agreement, Buyer Parent entered into voting and support agreements (each, a “ Voting and Support Agreement ”) with each equityholder (and certain affiliates of any such equityholder) of Buyer Parent or any subsidiary of Buyer Parent that is also a shareholder of the Company, which shareholders collectively held approximately 21.3% of the total outstanding voting shares of the Company and includ…

Entry into a Material Definitive Agreement. The Asset Purchase Agreement On May 11, 2023, Cyclerion Therapeutics, Inc., a Massachusetts corporation (the “ Company ”, “ we ”, “ us ” or “ our ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with JW Celtics Investment Corp., a Delaware corporation (“ Buyer Parent ”) and JW Cycle Inc., a Delaware corporation (“ Buyer ” and together with Buyer Parent, “ Buyers ”), pursuant to which the Company has agreed, subject to c…

Unregistered Sales of Equity Securities. As previously announced, on March 31, 2023, the Company entered into an agreement (the “ Subscription Agreement ”) with Peter M. Hecht, Ph.D., our Chief Executive Officer and a member of the Board, for him to make an equity investment in the Company of $5,000,000 in cash for common stock or nonvoting Series A convertible preferred stock of the Company, the purchase price, consistent with Nasdaq rules, to be at or above the market price at the time of s…